Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 237

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 237
---
 (2022-$nil).

10. Loss per share

Net loss per common share represents net loss attributable to common shareholders divided by the weighted average number of common shares outstanding during the period.

Diluted loss per common share is calculated by dividing the applicable net loss by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the period.

|                                                                      |   | December 31, 2023 |     |   | December 31, 2022 |
|:---------------------------------------------------------------------|:--|------------------:|:----|:--|------------------:|
| Net loss attributable to shareholders                                | $ |         6,478,492 |     |   |         1,692,382 |
| Weighted average number of common shares outstanding during the year |   |         3,479,510 |     |   |         1,884,900 |
| Basic and diluted net loss per share attributable to shareholders    | $ |              1.86 |     | $ |              0.90 |

For all the periods presented, diluted loss per share equals basic loss per share due to the anti-dilutive effect of the note payable, convertible promissory notes, preferred shares and share options. The outstanding number and type of securities that could potentially dilute basic net loss per share in the future but would have decreased the loss per share (anti-dilutive) presented for the years ended December 31, 2023 and 2022 are as follows:

|                              |     | December 31, 2023 |     | December 31, 2022 |
|:-----------------------------|:----|------------------:|:----|------------------:|
|                              |     |                 # |     |                 # |
| Note payable                 |     |                   |     |            33,276 |
| Convertible promissory notes |     |                 - |     |           457,935 |
| Preferred shares             |     |                 - |     |         3,162,747 |
| Share options                |     |           812,500 |     |                 - |
| Total dilutive shares        |     |           812,500 |     |         3,653,958 |

<div align='center'>F-41</div>

11. Income taxes

Medicus Parma Ltd intends to be treated as a United States corporation for